caution larry

Hi, I’m Kim! This site provides a little insight to my journey of being diagnosised with Remitting Relapsing Multiple Sclerosis on October 26th 2004. I review books and documentaries, post MS-related news, and share my photos.

Subscribe (RSS)

no larry

My bloglines



November 2004
December 2004
January 2005
February 2005
March 2005
April 2005
May 2005
June 2005
July 2005
August 2005
September 2005
October 2005
November 2005
December 2005
January 2006
February 2006
March 2006
April 2006
May 2006
June 2006
July 2006
August 2006
September 2006
October 2006
November 2006
December 2006
January 2007
February 2007
March 2007
April 2007
May 2007
June 2007
July 2007
August 2007
September 2007
October 2007
November 2007
December 2007
January 2008
February 2008
March 2008
April 2008
May 2008
June 2008
July 2008
August 2008
September 2008
October 2008
November 2008
December 2008
January 2009
February 2009
March 2009
April 2009
May 2009
June 2009
July 2009
August 2009
September 2009
October 2009
November 2009
December 2009
January 2010
February 2010
March 2010
May 2010
June 2010
July 2010
September 2010
November 2011


Thursday, June 21, 2007
Tracing MS From Childhood to Adulthood

A new study out is finding that childhood MS takes longer to develop disability in walking by 10 years over average aged (32) adult diagnosed MS. Very interesting. It'd be great if they could figure out why though! "When MS started in childhood, it took about 10 years longer to worsen to the point at which patients had trouble walking, the study shows. But childhood cases began nearly 20 years earlier than adult-onset cases. So even with the decade of delay in worsening symptoms, patients with childhood-onset MS were younger than adult patients when walking became difficult. "Patients with childhood-onset multiple sclerosis take longer to reach states of irreversible disability but do so at a younger age than patients with adult-onset multiple sclerosis," write the researchers. It's not clear why childhood-onset MS took longer to worsen to that point than adult-onset MS. About half of the children with MS took drugs that target the immune system, but "none of these drugs has a proven effect on the long-term development of disability," write the researchers."

Tovaxin keeps giving positive results from the lastest trials

I'm facinated by this therapy and where it will go... 92%reduction in relapses? Damn, thats a good number! "The one-year extension clinical trial enrolled 8 subjects. Tovaxin therapy achieved a 92% reduction in annualized relapse rate in patients who received two treatment doses of Tovaxin eight weeks apart and were monitored for an additional 44 weeks. Patients enrolled in the extension clinical trial were earlier treated with a T-cell vaccine developed from myelin basic protein reactive T-cells. The company noted that data from the extension trial indicates that subjects previously treated with T-cell vaccine can be safely and effectively retreated with Tovaxin. The Tovaxin Phase IIb clinical study known as TERMS will include 150 patients and will evaluate the efficacy, safety and tolerability of the Tovaxin T- cell vaccination with clinically isolated syndrome and relapsing-remitting multiple sclerosis patients. Opexa completed patient enrollment in the 52-week TERMS study on May 17, 2007. All patients who complete the TERMS trial will be eligible to participate in an optional one-year extension study.

Enrollment Begins For Study Of MBP8298 In Secondary-Progressive

I do believe there are some readers here who are interested in this potential drug... so here's some more news coming out about it. "Eligibility and Details: To enroll in this phase III study, people must be 18-65 years of age, with a documented history of secondary-progressive MS. Only people who are positive for the HLA DR2 and/or DR4 genes can participate; a blood test will be taken to determine HLA status. Participants must have had no relapse in the 3 months before the study. Participants will be randomly assigned to receive either 500 mg of MBP8298 or inactive placebo intravenously every six months for two years. The primary goal of the study is to determine the effectiveness of MBP8298 as measured by the EDSS, a widely used rating system of clinical status. Secondary objectives are to assess the drug's effects on disease activity observed on MRI (magnetic resonance imaging scans), relapse rates, quality of life and fatigue. Contact: For information on sites that are currently enrolling, please consult the study's listing on

TRIMESTA (oral estriol) potential oral med in trial

Did I read this right? This trial for an oral med is only for women with MS? Err... I think there's a gender missing in the MS population that might need a treatment option! Okay, so this is a drug already in use elasewhere in the world for menopause in women! No wonder men wouldn't be taking this drug... Anyways, they just got a $5 million grant from the NMSS and are recruiting. "TRIMESTA is an orally active, immunomodulatory and anti-inflammatory molecule the has been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes, but has never been introduced in North America. Estriol, the active ingredient in TRIMESTA, is a weak estrogenic-based molecule that is produced in the placenta by women during pregnancy. Estriol is considered to play an important role in the immunologic privilege offered to the fetus during pregnancy and is also thought to be responsible for the spontaneous remission of Th1-mediated autoimmune diseases of women (such as multiple sclerosis and rheumatoid arthritis) during pregnancy, especially during the third trimester."